Jury Sides with Mead Johnson in Preterm Formula Case, Positive for Abbott's Similar Litigation
ABT sits 16% above its 52-week low of $81.97.
Summary
A Missouri jury sided with Mead Johnson, a Reckitt unit, in a lawsuit alleging its preterm baby formula caused necrotizing enterocolitis (NEC). This verdict is a positive development for Abbott Laboratories, which faces nearly 1,000 similar lawsuits regarding its Similac formulas. The outcome provides a favorable precedent in a significant product liability area, potentially influencing future trial results or settlement discussions for Abbott and reducing its legal overhang. This follows the recent news that the Department of Justice dropped its criminal investigation into Abbott's baby formula factory.
At the time of this announcement, ABT was trading at $94.83 on NYSE in the Life Sciences sector, with a market capitalization of approximately $165.2B. The 52-week trading range was $81.97 to $137.49. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Reuters.